Evolving racial/ethnic disparities in AML survival in the novel therapy era
Open Access
- 31 January 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (3) , 533-544
Abstract
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with newly diagnosed AML using data from a nationwide electronic health record–derived deidentified database. Patients were categorized based on their diagnosis date relative to venetoclax approval, as pre–novel therapy era (Pre era; 2014-2018; n = 2998) or post–novel therapy era (Post era; 2019-2022; n = 2098). Patients in the Post era were older and had more comorbidities than Pre era. Non-Hispanic Black (NHB) and Hispanic patients were younger and more likely to have lower socioeconomic status than non-Hispanic White (NHW) patients, with no differences in the distributions of key disease features. After accounting for age and comorbidity, overall survival (OS) was higher in patients in Post era than Pre era (adjusted hazard ratio [aHR], 0.90; 95% confidence interval [CI], 0.83-0.96). In Pre era, NHB had a 22% higher hazard of death than NHW (aHR, 1.22; 95% CI, 1.04-1.43), whereas worse OS was not observed for NHB in Post era (aHR, 0.86; 95% CI, 0.69-1.08; predicted 2-year survival, 45.3% vs 39.9%). Utilization of novel therapeutics in frontline therapy did not differ by race/ethnicity. Among patients receiving venetoclax-based induction, particularly those without TP53, RAS, or FLT3-ITD mutations, results suggested higher OS for NHB than NHW patients (aHR, 0.67; 95% CI, 0.45-1.01). Additional studies are needed to elucidate factors contributing to these observed survival differences and to inform strategies to optimize outcomes for all patients with AML.Keywords
This publication has 57 references indexed in Scilit:
- AML treatment: conventional chemotherapy and emerging novel agentsTrends in Pharmacological Sciences, 2024
- Changing frontline AML treatment patterns from 2013 to 2022Leukemia Research, 2023
- Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and FinancialOncology and Therapy, 2023
- Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population‐based analysis in the modern eraCancer, 2021
- Acute myeloid leukemia: current progress and future directionsBlood Cancer Journal, 2021
- Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of MortalityJAMA Oncology, 2017
- Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysisLeukemia Research, 2014
- Understanding disparities in leukemia: a national studyCancer Causes & Control, 2012
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Socioeconomic status and breast cancer incidence in California for different race/ethnic groupsCancer Causes & Control, 2001